Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers

Pharmacogenomics

Volumn 13, Issue 10, 2012, Pages 1129-1139

  Oved, Keren ^a   Morag, Ayelet ^a   Pasmanik Chor, Metsada ^a   Oron Karni, Varda ^a   Shomron, Noam ^a   Rehavi, Moshe ^a   Stingl, Julia C ^b,c   Gurwitz, David ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

CHL1; genome wide expression profiling; let 7b; let 7c; miR 132; miR 151 3p; miR 212; miR 30b; selective serotonin reuptake inhibitors

Indexed keywords

LET 7B; LET 7C; MICRORNA; MICRORNA 132; MICRORNA 151 3P; MICRORNA 212; MICRORNA 30B; PAROXETINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; LYMPHOCYTE; MICROARRAY ANALYSIS; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; SCREENING;

BIOMARKERS, PHARMACOLOGICAL; CELL ADHESION MOLECULES; CELL LINE, TRANSFORMED; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME, HUMAN; HUMANS; MICRORNAS; PAROXETINE; SEROTONIN UPTAKE INHIBITORS;

EID: 84865322046     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.93     Document Type: Article

References (58)

1. Souery D, Oswald P, Massat I et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J. Clin. Psychiatry 68(7), 1062-1070 (2007). (Pubitemid 47340327)
2. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9(5), 442-473 (2004). (Pubitemid 38903502)
3. Gelenberg AJ. A review of the current guidelines for depression treatment. J. Clin. Psychiatry 71(7), e15 (2010).
4. Ising M, Lucae S, Binder EB et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 66(9), 966-975 (2009).
5. Garriock HA, Kraft JB, Shyn SI et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 67(2), 133-138 (2010).
6. Uher R, Perroud N, Ng MY et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 167(5), 555-564 (2010).
7. Clark SL, Adkins DE, Aberg K et al. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychol. Med. 42(6), 1151-1162] (2012).
8. Goldstein DB. Common genetic variation and human traits. N. Engl. J. Med. 360(17), 1696-1698 (2009).
9. Morag A, Pasmanik-Chor M, Oron-Karni V, Rehavi M, Stingl JC, Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics 12(2), 171-184 (2011).
10. Berezikov E. Evolution of microRNA diversity and regulation in animals. Nat. Rev. Genet. 12(12), 846-860 (2011).
11. Long JM, Lahiri DK. Advances in MicroRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders. Exp. Neurol. 235(2), 402-418 (2012).
12. Yoo AS, Sun AX, Li L et al. MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 476(7359), 228-231 (2011).
13. Shomron N. MicroRNAs and Pharmacogenomics. Pharmacogenomics 11(5), 629-632 (2010).
14. Mouillet-Richard S, Baudry A, Launay JM, Kellermann O. MicroRNAs and depression. Neurobiol. Dis. 46(2), 272-278 (2012).
15. O'Connor RM, Dinan TG, Cryan JF. Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression. Mol. Psychiatry 17(4), 359-376 (2012).
16. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 329(5998), 1537-1541 (2010).
17. Morag A, Kirchheiner J, Rehavi M, Gurwitz D. Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. Pharmacogenomics 11(3), 327-340 (2010).
18. Wong CK, Lau KM, Chan IH et al. MicroRNA-21* regulates the prosurvival effect of GM-CSF on human eosinophils. Immunobiology doi:10.1016/j.imbio. 2012.05.019 (2012) (Epub ahead of print).
19. Galiveti CR, Rozhdestvensky TS, Brosius J, Lehrach H, Konthur Z. Application of housekeeping npcRNAs for quantitative expression analysis of human transcriptome by real-time PCR. RNA 16(2), 450-461 (2010).
20. Mestdagh P, Van Vlierberghe P, De Weer A et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 10, R64 (2009).
21. Zhang W, Dolan ME. Use of cell lines in the investigation of pharmacogenetic loci. Curr. Pharm. Des. 15(32), 3782-3795 (2009).
22. Coulombe-Huntington J, Lam KC, Dias C, Majewski J. Fine-scale variation and genetic determinants of alternative splicing across individuals. PLoS Genet. 5(12), e1000766 (2009).
23. Bleibel WK, Duan S, Huang RS et al. Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum. Genet. 125(2), 173-180 (2009).
24. Dolan ME, Newbold KG, Nagasubramanian R et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 64(12), 4353-4356 (2004). (Pubitemid 38802443)
25. Hartford CM, Duan S, Delaney SM et al. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113(10), 2145-2153 (2009).
26. Huang RS, Duan S, Bleibel WK et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc. Natl Acad. Sci. USA 104(23) 9758-9763 (2007). (Pubitemid 47175340)
27. Pinto N, Ludeman SM, Dolan ME. Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 10(12), 1897-1903 (2009).
28. Li L, Fridley B, Kalari K et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res. 68(17), 7050-7058 (2008).
29. Fry RC, Svensson JP, Valiathan C et al. Genomic predictors of interindividual differences in response to DNA damaging agents. Genes Dev. 22(19), 2621-2626 (2008).
30. Wheeler HE, Dolan ME. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 13(1), 55-70 (2012).
31. Jepson JE, Reenan RA. RNA editing in regulating gene expression in the brain. Biochim. Biophys. Acta 1779, 459-470 (2008).
32. Wheeler G, Ntounia-Fousara S, Granda B, Rathjen T, Dalmay T. Identification of new central nervous system specific mouse microRNAs. FEBS Lett. 580, 2195-2200 (2006).
33. Gardiner E, Beveridge NJ, Wu JQ et al. Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol. Psychiatry doi:10.1038/mp.2011.78 (2011) (Epub ahead of print).
34. Guidi M, Muiños-Gimeno M, Kagerbauer B et al. Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. BMC Mol. Biol. 11, 95 (2010).
35. Zhao C, Sun G, Li S et al. MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. Proc. Natl Acad. Sci. USA 107(5), 1876-1881 (2010).
36. Wulczyn FG, Smirnova L, Rybak A et al. Post-transcriptional regulation of the let-7 microRNA during neural cell specification. FASEB J. 21(2), 415-426 (2007). (Pubitemid 46213489)
37. Zhou R, Yuan P, Wang Y et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34(6), 1395-1405 (2009).
38. Rinaldi A, Vincenti S, De Vito F et al. Stress induces region specific alterations in microRNAs expression in mice. Behav. Brain Res. 208, 265-269 (2010).
39. Luikart BW, Perederiy JV, Westbrook GL. Dentate gyrus neurogenesis, integration and microRNAs. Behav. Brain Res. 227(2), 348-355 (2012).
40. Magill ST, Cambronne XA, Luikart BW et al. microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc. Natl Acad. Sci. USA 107(47), 20382-20387 (2010).
41. Luikart BW, Bensen AL, Washburn EK et al. miR-132 mediates the integration of newborn neurons into the adult dentate gyrus. PLoS ONE 6(5), e19077 (2011).
42. Numakawa T, Yamamoto N, Chiba S et al. Growth factors stimulate expression of neuronal and glial miR-132. Neurosci. Lett. 505(3), 242-247 (2011).
43. Liu NK, Wang XF, Lu QB, Xu XM. Altered microRNA expression following traumatic spinal cord injury. Exp. Neurol. 219(2), 424-429 (2009).
44. Wanet A, Tacheny A, Arnould T, Renard P. miR-212/132 expression and functions: within and beyond the neuronal compartment. Nucleic Acids Res. 40(11), 4742-4753 (2012).
45. Maness PF, Schachner M. Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat. Neurosci. 1, 19-26 (2007). (Pubitemid 46026522)
46. Montag-Sallaz M, Schachner M, Montag D. Misguided axonal projections, neural cell adhesion molecule 180 mRNA upregulation, and altered behavior in mice deficient for the close homolog of L1. .Mol. Cell Biol. 22(22), 7967-7981 (2002). (Pubitemid 35217305)
47. Montag-Sallaz M, Baarke A, Montag D. Aberrant neuronal connectivity in CHL1-deficient mice is associated with altered information processing-related immediate early gene expression. .J. Neurobiol. 57(1), 67-80 (2003). (Pubitemid 37087787)
48. Morellini F, Lepsveridze E, Kähler B, Dityatev A, Schachner M. Reduced reactivity to novelty, impaired social behavior, and enhanced basal synaptic excitatory activity in perforant path projections to the dentate gyrus in young adult mice deficient in the neural cell adhesion molecule CHL1. Mol. Cell. Neurosci. 34(2), 121-136 (2007). (Pubitemid 46136990)
49. Demyanenko GP, Siesser PF, Wright AG et al. L1 and CHL1 cooperate in thalamocortical axon targeting. Cereb. Cortex 21(2), 401-412 (2011).
50. Chen QY, Chen Q, Feng GY et al. Case-control association study of the close homologue of L1 (CHL1) gene and schizophrenia in the Chinese population. Schizophr. Res. 73(2-3), 269-274 (2005). (Pubitemid 40093889)
51. Frints SG, Marynen P, Hartmann D et al. CALL interrupted in a patient with non-specific mental retardation: gene dosage dependent alteration of murine brain development and behavior. Hum. Mol. Genet. 12(13), 1463-1474 (2003). (Pubitemid 36857295)
52. Desarnaud F, Jakovcevski M, Morellini F, Schachner M. Stress downregulates hippocampal expression of the adhesion molecules NCAM and CHL1 in mice by mechanisms independent of DNA methylation of their promoters. Cell Adh. Migr. 2(1), 38-44 (2008).
53. Castrén E, Võikar V, Rantamäki T. Role of neurotrophic factors in depression. Curr. Opin. Pharmacol. 7(1), 18-21 (2007). (Pubitemid 46238033)
54. Benusková L. Antidepressants and synaptic plasticity: a hypothesis. Med. Hypotheses 35(1), 17-22 (1991).
55. Gorman JM, Docherty JP. A hypothesized role for dendritic remodeling in the etiology of mood and anxiety disorders. J. Neuropsychiatry Clin. Neurosci. 22(3), 256-264 (2010).
56. Bjartmar L, Alkhori L, Ruud J et al. Long-term treatment with antidepressants, but not environmental stimulation, induces expression of NP2 mRNA in hippocampus and medial habenula. Brain Res. 1328, 25-33 (2010).
57. Chen F, Madsen TM, Wegener G, Nyengaard JR. Imipramine treatment increases the number of hippocampal synapses and neurons in a genetic animal model of depression. Hippocampus 20(12), 1376-1384 (2010).
58. Im HI, Kenny PJ. MicroRNAs in neuronal function and dysfunction. Trends Neurosci. 35(5), 325-334 (2012).